Company Overview
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.
Why Investors Should Care
Revenue has grown at a 16.5% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $206.13M (+14.3% YoY); net profit $-15.63M.
- Trailing 12 Months Year-on-year growth — revenue +9.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 16.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 16.47% |
| 1 Year: | 9.50% |
Stock Price Performance
| 1 Year: | +94.74% |
| 6 Months: | +34.20% |
| 3 Months: | -4.43% |
| 1 Month: | +11.64% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)43.66 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 16.5% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CERS Cerus Corporation R2KR3KPHARMA | 2.59 | -86.33 | $521.95M | 0.00% | -7.17% | -10.77% | 16.47% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 9.53M | 10.80M | - | - | 15.42M | 15.40M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 43.24M | - | - | 53.66M | 57.44M |
| Gross Profit | 2.98M | 1.80M | 2.48M | 3.49M | 3.37M | 4.28M | 4.72M | 4.52M | 3.31M | 5.17M | 5.45M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -14.37M | -15.53M | -16.19M | - | -15.35M | -16.74M | -14.26M | - | -18.09M | -16.20M | -12.38M | - | -13.36M | -12.57M | -13.60M | - | -16.07M | -16.79M | -16.96M | - | -15.40M | -14.61M | -13.98M | -16.45M | -14.40M | -11.13M | -9.85M | -6.83M | -7.45M | -14.15M | -11.64M | -5.24M | -7.98M | -3.84M | -961.00K | -5.85M | -3.42M | 1.24M | -354.00K | -1.86M |
| Net Income | -9.46M | -15.97M | -15.68M | -14.76M | -16.86M | -18.17M | -14.38M | -13.50M | -18.60M | -17.08M | -13.42M | -11.49M | -13.88M | -13.28M | -14.19M | -16.20M | -18.79M | -17.56M | -17.97M | -16.92M | -16.47M | -14.87M | -14.14M | -17.46M | -15.36M | -12.44M | -12.28M | -8.39M | -8.48M | -15.62M | -13.28M | -7.27M | -9.69M | -5.78M | -2.93M | -7.72M | -5.71M | -19.00K | -1.64M | -2.94M |
| Diluted EPS | -0.17 | -0.17 | -0.17 | -0.15 | -0.17 | -0.18 | -0.14 | -0.13 | -0.18 | -0.16 | -0.12 | -0.10 | -0.11 | -0.10 | -0.11 | -0.12 | -0.14 | -0.13 | -0.13 | -0.12 | - | - | - | - | - | -0.07 | -0.07 | -0.05 | -0.05 | -0.09 | -0.07 | -0.04 | -0.05 | -0.03 | -0.02 | -0.04 | -0.03 | 0.00 | -0.01 | -0.01 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.98M | 23.11M | 33.04M | 36.79M | 39.66M | 36.42M | 34.22M | 39.27M | 51.33M | 76.05M | 93.77M | 114.25M | 159.52M | 162.05M | 156.37M | 180.27M | 206.13M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.95M | 69.97M | 80.75M | 93.84M |
| Gross Profit | 5.40M | 9.63M | 12.07M | 16.08M | 17.05M | 15.23M | 10.76M | 16.89M | - | - | - | - | - | 87.09M | 86.40M | 99.52M | 112.29M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 121.17M | 112.72M | 113.75M | 120.97M |
| Operating Income | -23.83M | -15.96M | -15.92M | -17.30M | -28.30M | -44.50M | -61.08M | -61.45M | -57.53M | -54.99M | -66.23M | -58.33M | -48.94M | -34.08M | -26.32M | -14.22M | -8.68M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -33.52M | -26.34M | -10.02M | -5.51M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.83M | 8.39M | 8.88M | 8.34M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -42.34M | -37.32M | -20.76M | -15.28M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 488.00K | 325.00K | 205.00K | 354.00K |
| Net Income | -24.14M | -16.91M | -16.98M | -15.92M | -43.34M | -38.76M | -55.87M | -62.91M | -60.59M | -57.56M | -71.24M | -59.86M | -54.37M | -42.78M | -37.49M | -20.92M | -15.63M |
| Diluted EPS | -0.69 | -0.42 | -0.35 | -0.33 | -0.64 | -0.61 | -0.61 | -0.62 | -0.56 | -0.44 | - | -0.37 | -0.32 | -0.24 | -0.21 | -0.11 | -0.08 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 48.17M | 45.37M | 48.92M | 83.38M | 81.78M | 139.40M | 103.48M | 98.24M | 163.46M | 165.53M | 221.41M | 237.50M | 218.09M | 197.75M | 200.92M | 221.86M |
| Total Equity | 34.28M | 21.45M | 23.73M | 18.31M | 19.11M | 42.80M | 41.52M | 94.77M | 57.79M | 38.94M | 84.52M | 57.05M | 103.81M | 84.62M | 67.61M | 52.65M | 56.15M | 64.22M |
| Cash & Equivalents | 10.30M | 17.29M | 28.95M | 25.50M | 26.70M | 29.48M | 22.78M | 71.02M | 22.56M | 13.68M | 28.86M | 34.99M | 36.59M | 48.76M | 35.59M | 11.65M | 20.27M | 19.96M |
| Long Term Debt | - | - | - | - | - | - | 10.00M | 20.00M | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 24.43M | 27.05M | 29.81M | 40.59M | 40.26M | 44.64M | 45.69M | 59.30M | 78.94M | 108.48M | 117.61M | 151.88M | 149.53M | 144.30M | 144.02M | 156.89M |
| Current Liabilities | - | - | 19.70M | 21.11M | 25.61M | 39.42M | 29.19M | 21.86M | 26.89M | 23.13M | 52.68M | 50.34M | 59.97M | 78.56M | 117.06M | 67.52M | 63.61M | 100.80M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.55M | -14.27M | -15.63M | -13.92M | -26.80M | - | - | -53.53M | -52.23M | -31.25M | -65.50M | -41.81M | - | -25.61M | -43.17M | 11.36M | 4.84M |
| Investing Cash Flow | 9.32M | -70.00K | 563.00K | 205.00K | -29.06M | - | - | -19.92M | 421.00K | -43.85M | 28.18M | -49.56M | - | 8.46M | 8.62M | -8.13M | -6.17M |
| Financing Cash Flow | 12.21M | 26.00M | 11.62M | 14.91M | 58.64M | - | - | 24.57M | 43.00M | 92.75M | 43.49M | 91.78M | - | 4.19M | 10.67M | 4.96M | 231.00K |
| Capital Expenditure | -191.00K | -1.69M | -158.00K | -81.00K | -663.00K | -2.11M | -722.00K | -563.00K | -353.00K | -1.14M | -8.94M | -1.61M | - | -2.00M | -4.60M | -2.84M | -3.73M |
| Free Cash Flow | -14.74M | -15.96M | -15.79M | -14.00M | -27.46M | - | - | -54.09M | -52.59M | -32.39M | -74.43M | -43.43M | - | -27.61M | -47.77M | 8.52M | 1.11M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.96M | -23.87M | 8.19M | -1.10M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 30.0% | 41.7% | 36.5% | 43.7% | 43.0% | 41.8% | 31.4% | 43.0% | - | - | - | - | - | 53.7% | 55.3% | 55.2% | 54.5% |
| Operating Margin % | -132.5% | -69.1% | -48.2% | -47.0% | -71.4% | -122.2% | -178.5% | -156.5% | -112.1% | -72.3% | -70.6% | -51.1% | -30.7% | -21.0% | -16.8% | -7.9% | -4.2% |
| Net Margin % | -134.2% | -73.2% | -51.4% | -43.3% | -109.3% | -106.4% | -163.2% | -160.2% | -118.0% | -75.7% | -76.0% | -52.4% | -34.1% | -26.4% | -24.0% | -11.6% | -7.6% |
| ROE % | -112.5% | -71.3% | -92.7% | -83.3% | -101.3% | -93.3% | -59.0% | -108.9% | -155.6% | -68.1% | -124.9% | -57.7% | -64.3% | -63.3% | -71.2% | -37.3% | -24.3% |
| ROCE % | - | -56.1% | -65.7% | -74.2% | -64.4% | -84.6% | -52.0% | -80.2% | -76.6% | -49.6% | -57.5% | -36.1% | -30.8% | -33.7% | -20.2% | -10.4% | -7.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 11.02% | 22.22M | $58.87M |
| 2 | ARK Investment Management, LLC | 8.90% | 17.93M | $47.52M |
| 3 | Vanguard Capital Management LLC | 4.25% | 8.56M | $22.69M |
| 4 | Baker Bros. Advisors, LP | 3.17% | 6.40M | $16.95M |
| 5 | Shaw D.E. & Co., Inc. | 2.72% | 5.49M | $14.54M |
| 6 | Geode Capital Management, LLC | 2.54% | 5.12M | $13.57M |
| 7 | State Street Corporation | 2.36% | 4.75M | $12.60M |
| 8 | Senvest Management LLC | 2.29% | 4.61M | $12.23M |
| 9 | Acadian Asset Management. LLC | 2.12% | 4.27M | $11.32M |
| 10 | Sumitomo Mitsui Trust Group, Inc. | 2.05% | 4.14M | $10.97M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CERS
Cerus Stock Price Forecast. Should You Buy CERS? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE45UjVFVHpoNDZCUTl3b2xwRGJyQnZIX3Z2MWJmUGVEdm92M0MtYWItY1hBUF96UWZObzFCRzFpSG9mZTMyRW5lNg?oc=5" target="_blank">Cerus Stock Price Forecast. Should You Buy CERS?</a> <font…
Cerus (NASDAQ:CERS) Upgraded at Wall Street Zen - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQdVR0Vzh1SEFZd2NLSjQxZkNyUXBJYk5BNkk3eWxqNnQyVjd0Mzd4UlBJNHJkZ2h4M2xxa3VvV0V1elU2NEFFVTV6MTFHQXZqNk5GcGtVVDhRWFNRZE9IeThJZUZZclVyMWRrZ0NHZ01rTUZGNGdtYk1SbjJtdWt1ZHdRenl0d1AtNkV4NE…
Cerus (CERS) Stock Sinks As Margin Pressure Deepens Despite Revenue Growth - simplywall.st
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxNOUZkeTFKU2U3TFZrekpKcFhqVmp3Q2NNZTlNYTZCSWR2Yzlxd09FNUp1ZXcwTzhHbVVfbVc4SVFJcFdjczFZa0hOZElnRW5QcjRXSmZ2MWtlQ2V4RDNqcUJneDBPYThEQWp2dWRGOEVXeFZZMHNXOXZ0LW5rd2tNTTJBOGpucGVoeDI3WG…
Cerus: This Blood-Safety Underdog Should Be Earning More Respect (NASDAQ:CERS) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPcng2amx1Y0ZyNGI1THpZRlFaUmp5Ql95VVlhSzVDS1J6SzNnbVRZN1pzaEkxNWhwS29NRjJsM002MHZqdGMxbVhVRlRveW9ua3JOdFNueTBCNndhd0Q3WnBBeDBTaEFpZHI5MXlBMHJMN2poSnRqaXVjYklET2NmMktsd2RQS0ZWTG5MNk…
$CERS stock is up 10% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNYkE1Tmd0YlZRbF9lZExrS2VyY1hVVGtIZkZFVFI4dmJnOFc1eVBSSGVzNFNrdDJ0bnNDSzBuU3F4aW5TWE1zTHNKYjBJekh6RHZpTXdjRU5SVHk2aGNLb3JyRTZFX0JFUDduMVlpYV9YN0dHNlVWUVk3SllsUmpkRUVQdkdTOHM5bHVRaW…
CERS - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5uZERPY050cDJ5akQwb2s5Ykg2Q1Y1Tm1XTVNFaUJGU2VzTndFdzJhdk5leWQ0YkVIaUtacTZXV0toN25HNkE?oc=5" target="_blank">CERS</a> <font color="#6f6f6f">Finviz</font>…
CERS — Frequently Asked Questions
What is the current share price of Cerus Corporation (CERS)?
As of 2026-09-07 16:24 PDT, Cerus Corporation (CERS) trades at $2.59 on NasdaqGM. Its 52-week range is $1.16 to $3.28.
What is the market capitalisation of CERS?
Cerus Corporation (CERS) has a market capitalisation of $521.95M on NasdaqGM.
What is the P/E ratio of CERS?
CERS trades at a trailing price-to-earnings (P/E) ratio of -86.33. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 6.75.
What is the return on equity (ROE) of CERS?
CERS has a return on equity (ROE) of -10.77%. Its return on capital employed (ROCE) is -7.17%.
Is CERS a good stock to buy?
This page provides a data-driven analysis of Cerus Corporation (CERS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.